Can alprazolam (Xanax) be taken together with suvorexant (Belsomra)?

Combining Xanax and Belsomra: Not Recommended Without Dose Reduction

The combination of alprazolam (Xanax) and suvorexant (Belsomra) significantly increases the risk of CNS depression, next-day impairment, falls, and complex sleep behaviors; if co-administration is necessary, dosage reduction of both medications is required, though avoiding this combination is preferable. 1

Primary Safety Concerns

The FDA label for Belsomra explicitly warns that co-administration with benzodiazepines like alprazolam increases the risk of CNS depression and requires dosage adjustments of both medications due to potentially additive effects 1. This is not a theoretical concern—the combination creates multiple overlapping risks:

Specific Risks of This Combination:

• Enhanced CNS depression leading to excessive sedation that may persist for several days
• Increased next-day impairment, including dangerous driving impairment that may not be subjectively apparent to the patient
• Higher fall risk, particularly concerning in elderly patients
• Complex sleep behaviors (sleep-walking, sleep-driving, eating while asleep) that can occur with or without awareness 1
• Cognitive and behavioral changes that may not be reliably detected by routine clinical examination

Clinical Decision Algorithm

If the combination cannot be avoided:

1. Reduce Belsomra dose: Use 5 mg (the lowest available dose) rather than the standard 10 mg starting dose 1
2. Reduce alprazolam dose: Lower the benzodiazepine dose from baseline
3. Ensure ≥7 hours sleep time: Patient must have full night remaining before needing to be alert
4. Absolute alcohol prohibition: Warn patient explicitly about additive effects 1
5. No driving the next day: Particularly after initial doses, as impairment can occur without subjective awareness

Better alternatives to consider:

• Taper and discontinue alprazolam before initiating Belsomra
• Use Belsomra alone at standard dosing (10-20 mg) for insomnia management
• Consider cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment per guidelines 2

Critical Warnings

The FDA label emphasizes that CNS depressant effects may persist for several days after discontinuing Belsomra, meaning the interaction risk doesn't immediately resolve 1. Patients often cannot reliably detect their own impairment—formal testing shows driving impairment even when patients feel normal 1.

Elderly patients face compounded risks: Both medications increase fall risk independently; combined use substantially elevates this danger 1.

Monitoring Requirements

If this combination is used despite recommendations:

• Assess for excessive daytime somnolence at every encounter
• Screen for any new behavioral symptoms or complex sleep behaviors
• Monitor for falls, particularly in elderly patients
• Evaluate for worsening depression or suicidal ideation (Belsomra carries this warning) 1
• Consider discontinuation if any concerning symptoms emerge

The evidence from insomnia treatment guidelines shows that while Belsomra (suvorexant) improves sleep outcomes, the comparative effectiveness versus other approaches remains unclear, and pharmacotherapies carry risks of cognitive/behavioral changes 2. Adding a benzodiazepine to this regimen amplifies these concerns without clear benefit, making monotherapy strongly preferable when pharmacologic treatment is indicated.